You are here

Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia

Last updated on November 10, 2019

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumonia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-90 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- MRSA and pneumonia cases by ICD-9 code identification.

- Diagnosis included during inpatient stay.

- Treatment initiation in hospital.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Death of discharge within 3 days of treatment initiation.

- Exposure to other treatments with MRSA activity.

NCT01819935
Pfizer
Completed
Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia
NCT04040621
All Genders
0+
Years
Multiple Sites
Descriptive Information
Brief TitleClinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia
Official TitleClinical Outcomes Among a National Veterans Affairs Methicillin Resistant Staphylococcus Aureus (MRSA) Pneumonia Cohort Treated With Linezolid Or Vancomycin
Brief SummaryThe purpose of this non-interventional, retrospective study of existing data is to evaluate clinical outcomes related to Methicillin-resistant Staphylococcus aureus hospital based pneumonia by treatment and among subpopulations.
Detailed DescriptionAll patients meeting inclusion/exclusion criteria from inpatient database from 1/1/02-9/30/10.
Study TypeObservational
Study DesignObservational Model: Cohort
Time Perspective: Retrospective
Target Follow-Up DurationNot Provided
BiospecimenNot Provided
Sampling MethodNon-Probability Sample
Study PopulationNational database of inpatient admissions between January 1, 2002 and Septmeber 30, 2010
ConditionPneumonia
Intervention
  • Drug: linezolid (Zyvox)
    As prescribed-this is retrospective cohort of existing clinical data.
  • Drug: vancomycin
    As prescribed-this is retrospective cohort of existing clinical data.
Study Groups/Cohorts
  • linezolid (Zyvox)
    Intervention: Drug: linezolid (Zyvox)
  • Vancomycin
    Intervention: Drug: vancomycin
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment StatusCompleted
Actual Enrollment
 (submitted: June 10, 2013)
5271
Original Actual Enrollment
 (submitted: March 22, 2013)
9814
Actual Study Completion DateJanuary 2013
Actual Primary Completion DateJanuary 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • MRSA and pneumonia cases by ICD-9 code identification.
  • Diagnosis included during inpatient stay.
  • Treatment initiation in hospital.

Exclusion Criteria:

  • Death of discharge within 3 days of treatment initiation.
  • Exposure to other treatments with MRSA activity.
Sex/Gender
Sexes Eligible for Study:All
Ages18 Years to 90 Years   (Adult, Older Adult)
Accepts Healthy VolunteersNo
ContactsContact information is only displayed when the study is recruiting subjects
Listed Location CountriesNot Provided
Removed Location Countries  
 
Administrative Information
NCT NumberNCT01819935
Other Study ID NumbersA5951163
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing StatementNot Provided
Responsible PartyPfizer
Study SponsorPfizer
CollaboratorsNot Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateDecember 2013

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now